Eli Lilly and Co at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everybody. I'm Chris Schott at JPMorgan. And it's my pleasure to be hosting a fireside chat with Eli Lilly's Chairman and CEO, Dave Ricks, today.
Dave, thanks for joining us. I know you always bring some great news to the conference, and certainly, the Alzheimer's update yesterday really kicked off the conference on a positive foot. I thought maybe just to open up, if you want to just make some general comments around your priorities for Lilly in 2021. Obviously, a lot of topics we can dig into from there but make some opening comments, and we'll go from there.
Absolutely. Well, thanks for having us, Chris, and look forward to talking about Alzheimer's later maybe. But 2020 was a kind of remarkable year in a lot of ways, and it sets up what we're focused on in '21, which is -- the first thing is we're in the middle of a strong growth period for the company, double-digit volume growth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
